A study in healthy volunteers to look at how COMP360 is taken up by the body when given as two different strength capsules

This open-label trial will assess the bioavailability of COMP360 (psilocybin) in healthy volunteers (n=14). The trial will assess the effects of both 5 and 25 mg doses of COMP360.

The overall aim of the trial is to explore how different doses of COMP360 are taken up by the body, further establish pharmacokinetic profiles and compare the safe and tolerability of single doses of 5 and 25 mg COMP360.

This trial is sponsored by COMPASS Pathways.

Topic Neuroscience
Compound Psilocybin
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.